INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Mellinghoff, IK; Van den Bent, MJ; Clarke, JL; Maher, EA; Peters, KB; Touat, M; De Groot, JF; De La Fuente, MI; Arrillaga-Romany, I; Wick, W; Ellingson, BM; Schoenfeld, S; Tai, F; Le, K; Lu, M; Steelman, L; Hassan, I; Pandya, SS; Wen, PY; Cloughesy, TF

Published Date

  • 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X